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Abstract
Genome-wide association studies (GWAS) have identifiednumerous commonprostate cancer (PrCa) susceptibility loci.Wehave
fine-mapped 64 GWAS regions known at the conclusion of the iCOGS study using large-scale genotyping and imputation in
25 723 PrCa cases and 26 274 controls of European ancestry. We detected evidence for multiple independent signals at 16
regions, 12 of which contained additional newly identified significant associations. A single signal comprising a spectrum of
correlated variationwas observed at 39 regions; 35 ofwhich are nowdescribed bya novelmore significantly associated lead SNP,
while the originally reported variant remained as the lead SNP only in 4 regions. We also confirmed two association signals in
Europeans that had beenpreviously reported only in East-AsianGWAS. Based on statistical evidence and linkage disequilibrium
(LD) structure, we have curated and narrowed down the list of the most likely candidate causal variants for each region.
Functional annotation using data from ENCODE filtered for PrCa cell lines and eQTL analysis demonstrated significant
enrichment for overlap with bio-features within this set. By incorporating the novel risk variants identified here alongside the
refined data for existing association signals, we estimate that these loci now explain ∼38.9% of the familial relative risk of PrCa,
an 8.9% improvement over the previously reported GWAS tag SNPs. This suggests that a significant fraction of the heritability of
PrCa may have been hidden during the discovery phase of GWAS, in particular due to the presence of multiple independent
signals within the same region.
Introduction
Prostate cancer (PrCa) is one of the most commonly diagnosed
cancers and leading causes of cancer-related deaths for men in
developed countries. An increased incidence of PrCa among
first-degree relatives of patients, together with results from
twin studies, provides strong evidence for a heritable component
to PrCa (1). In recent years, many studies have sought to identify
genetic variants that predispose towards the development of
PrCa. Candidate gene studies have demonstrated that rare
(minor allele frequency, MAF < 1%) loss-of-function variants in
DNA repair genes, in particular BRCA2, as well as a recurrentmis-
sense variant in HOXB13 confer moderately increased disease
risks; however, these explain only a limited fraction of the overall
heritability (2,3). In addition to these rare, higher risk mutations,
∼100 common, low-penetrance variants have currently been
identified through GWAS. These variants confer only modest
increases in risk individually, but appear to combine multiplica-
tively thereby exerting a more substantial effect that is currently
estimated to explain 33% of the familial relative risk (FRR) of the
disease (4).
The specific low penetrance variants identified in GWAS are
generally unlikely themselves to be causative for PrCa, since
they are typically correlated with many other variants, one or
more of which is functionally related to the disease. Fine-map-
ping studies are therefore performed to enable a more thorough
evaluation of variation in associated regions, in order to narrow
down the number of potential causal variants for subsequent
evaluation and validation through functional assays. In addition,
it has become clear that a small number of regions associated
with many traits harbor multiple independent association sig-
nals (a classic example ofwhich is the Chr8q24 region centromer-
ic to MYC, which is associated with many forms of cancer
including PrCa). However, in most cases, it is unclear whether
these independent signals modulate risk through a common or
separate functional mechanism, since the causal variants them-
selves remain unresolved. A key first step towards identifying the
precise causal variants and functional mechanisms that con-
fer risk is to comprehensively evaluate the evidence for associ-
ation for non-genotyped potentially relevant variants within
the region, to refine the original GWAS signal. In principle, re-
sequencing associated regions in large case–control series
would provide the most thorough data, but this approach is
currently prohibitively expensive for routine application. How-
ever, since GWAS signals are expected to be predominantly dri-
ven by relatively common variants, large-scale genotyping
together with imputation provides a cost-effective approach to
evaluate the majority of likely causal variants. To date, only a
small number of PrCa susceptibility loci have been fine-mapped.
In analyses conducted by the PRACTICAL Consortium, for which
the largest set of PrCa samples and genotype data are available,
we previously identified for the KLK3 locus at Chr19q13 a more
strongly associated missense coding variant that has been de-
monstrated to alter protein function (5), and at two regions,
Chr8q24 and TERT at Chr5p15, fine-mapping demonstrated the
presence of multiple independent risk variants (6,7). In this
study, we have fine-mapped, functionally annotated and curated
a set of the most promising candidate susceptibility variants for
all PrCa susceptibility regions published by the end of the iCOGS
genotyping project, aside from the three that we had previously
analyzed individually.
Results
We have fine-mapped 64 known PrCa regions through a combin-
ation of genotyping and imputation. Region boundaries for this
analysis were defined as 500 kb either side of any known PrCa as-
sociated GWAS SNPs; where such regions overlapped, they were
merged to form a single larger region (extended boundaries were
employed at regions Chr3p12, Chr4q22, Chr8p21, Chr11q13 and
Chr17q12). We used genotype data for 25 723 cases and 26 274
controls of European ancestry from two UK GWAS studies and
from the 32 studies in the PRACTICAL Consortium genotyped
using the iCOGS array. After imputation to a 1000 Genomes refer-
ence panel, data were available for 283 910 SNPs across these 64
regions. For 23 of the 64 regions the iCOGS array contained a
dense panel of markers that included almost all variants corre-
lated with the original GWAS hit, thereby facilitating particularly
high-resolution interrogation of these loci.
In this fine-mapping study, 15 previously reported PrCa sus-
ceptibility variants did not replicate at genome-wide significance
(P < 5 × 10−8). For four of these variants, the association with PrCa
had previously been reported only in East Asian populations
(rs1938781, rs2252004 (8) and rs9600079 (9) in Japanese and
rs103294 (10) in Chinese individuals). We found no evidence
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suggestive of association with PrCa at any of these regions in
individuals of European ancestry (P > 0.4), which may indicate
that these variantsmodulate risk through amechanismpredom-
inate among individuals with specific genetic backgrounds, or al-
ternatively require further confirmation in Europeans through
additional larger studies. For another variant that did not repli-
cate at genome-wide significance in this study, rs1571801, the
previously reported association with PrCa achieved statistical
significance only in relation to aggressive disease (11). In our
data, the most strongly associated correlated variant within
this region showed some tendency towards association with
PrCa although remained non-significant (rs200543781, OR = 1.36,
P = 5.1 × 10−4); this could reflect the fact that our sample panel
was not enriched for aggressive disease. A further four regions
had previously been identified in studies by the PRACTICAL Con-
sortium; however, in each case, a larger sample sizewas available
in the original study or consequent replication set than for this
fine-mapping analysis. For these four SNPs (rs6869841,
rs2427345 and rs11902236 published in Eeles et al. (12) and
rs6763931 in Kote-Jarai et al. (13)), P-values in this analysis were
close to genome-wide significance (Supplementary Material,
Table S1), and the failure to replicate at genome-wide signifi-
cance most likely reflects the smaller sample size. For the re-
maining six regions where the original index SNP did not reach
genome-wide significance, our recent meta-analysis that in-
cluded additional datasets (35 093 cases and 34 599 controls,
Amin Al Olama et al. (4)) observed associations at genome-wide
significance, and therefore these regions were included in this
analysis. Of the 55 regions in our final analysis (after excluding
the four non-European and five European regions which did not
reach genome-wide significance in this study or the meta-ana-
lysis), after stepwise logistic regression, 39 could be categorized
as ‘simple regions’ defined by a single association signal (Table 1)
and 16 as ‘complex regions’, each of which contained more than
one independent association signal (Table 2).
For each of the 75 independent association signals identified
across the 55 regions analyzed, we have selected a set of themost
promising correlated candidate causal variants. Since a greater
density of variants are interrogated during fine-mapping than
through the ‘tag SNP’ approach used in the discovery phase of
GWAS, the causal variants responsible for PrCa risk at each region
would generally be expected to associate with PrCa at a similar
level to the refined lead SNP, as well as exhibiting relatively
high levels of linkage disequilibrium (LD). Consequently, we se-
lected our ‘best candidate’ variants that most warrant further in-
terrogation for functionality and PrCa causality for each
association signal using an overlap between two criteria: likeli-
hood ratio of ≥1/1000 relative to the refined lead SNP (‘1000
worse’ list = 6537 SNPs) and correlation with the lead SNP at LD
r2 > 0.7 (LD list = 2202 SNPs). This best candidate list comprised
1623 SNPs across the 55 regions studied, with between 1 and 93
SNPs per association signal and a median of 13 candidate var-
iants (Supplementary Material, Table S2). These best candidate
SNPs were annotated for overlap with functional elements in
PrCa cell lines. For this analysis, bio-features were annotated ac-
cording to themethodology used in Hazelett et al.(14). Of our 1623
best candidate SNPs, 413 (25%) were either coding or within an
annotated bio-feature, with enhancer elements accounting for
the largest single class of element represented (Supplementary
Material, Table S2). We also analyzed the best candidate SNP
list for potential eQTLs using TCGA data available for prostate tis-
sue and amuch larger set of EuroBATS data for three different tis-
sue types (skin, LCL and adipose). To aid in the interpretation of
data from this study, we developed Locus Explorer, a Shiny R
application which allows the interactive graphical illustration
of all the regions we have fine-mapped and which can be
accessed at https://github.com/oncogenetics/LocusExplorer
(manuscript in preparation). In the Locus Explorer plots for this
study, we have included LD structure, statistical association
data, functional annotation, gene transcripts and eQTL data;
however, this application is customizable as required.
For 4 of the 39 simple regions, the originally reported SNP
remained the most strongly associated variant after fine-
mapping, whereas in the remaining 35 regions a new lead SNP
was identified (Table 1). The novel lead variants were generally
in strong (r2 > 0.7) or moderate LD (r2 = 0.3–0.7) with the original
GWAS tag SNP; however, for five regions, the new lead SNP was
only in weak LD with the original signal (r2 < 0.3). In 10 regions,
the originally reported variant was excluded from our set of the
best candidate SNPs to further investigate for possible causal
functional effects. A good illustration of the refinement of the as-
sociation signal within simple regions is at ChrXq12 where the
original signal, rs5919432, was situated 71 kb 3′ of the androgen
receptor (AR) gene. This has now been replaced by rs4446868
which is intronic toAR and in strong LDwith anumberof variants
within the coding sequence, while the original tag SNP did not re-
main among our list of the best candidate functional variants
(Table 1, Fig. 1A; Supplementary Material, Table S2). It may also
be possible to further prioritize the 46 selected candidate SNPs
at this region based on statistical and functional evidence; a clus-
ter of five variants were more strongly associated than the re-
mainder and these flank a known AR-binding site within intron
2 thathas been reported to function as an enhancer in LNCaP (15).
Two of the simple regions had been reported previously as
PrCa susceptibility variants only in East Asian populations
(rs1983891 at Chr6p21 and rs817826 at Chr9q31); in this study,
we have demonstrated for the first time that these loci are also
associated with PrCa risk in individuals with European ethnicity.
The lead SNP describing the association signal for Europeans at
Chr6p21, rs6458228, is strongly correlated with the Japanese hit
(r2 = 0.92); both are intronic in FOXP4 and in LDwith variants over-
lapping a number of bio-features. Our top European hit on
Chr9q31 near RAD23B, rs1771718, is not correlated (r2 = 0.03)
with the index SNP reported in the Chinese population and itself
overlaps a DNase1 hypersensitivity site in the LNCaP PrCa cell
line. Based on TCGA data, this signal is also an eQTL for
RAD23B in normal prostate tissue but not tumor (Table 1 and
Fig. 1B).
Of particular interest, within the 55 regions included in our
final analysis, we identified 16 ‘complex regions’ that harbor
more than one independent association signal after conditional
analysis and contained a total of 36 separate risk signals (Table 2).
Only five of these regions had previously been reported to con-
tain independently associated SNPs (CHMP2B at Chr3p12 (8,16),
PDLIM5 at Chr4q22 (17), SLC25A37/NKX3.1 at Chr8p21 (17),
Chr11q13 (16,18) and HNF1B at Chr17q12 (19,20)). At both
Chr3p12 andChr8p21, the two originally reported association sig-
nals arewithin 50 kb of one another however situated adjacent to
different genes. As this proximity fell comfortably within the
flanking distance we defined in this study for each region they
were nonetheless merged into a single region for this analysis.
Multiple independent risk variants within the same gene had
previously been identified within PDLIM5 and HNF1B, while
Chr11q13 is a gene desert previously reported to contain three in-
dependent hits. For all of these five regions thatwere known to be
complex prior to our fine-mapping, in this study, we confirmed
each of the previously reported independent associations, have
refined the spectrum of variation that best describes these
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association signals, and we have identified a novel, third inde-
pendent signal at HNF1B/Chr17q12. Furthermore, we have dis-
covered additional novel signals within 11 regions previously
known to contain only a single risk variant.
To illustrate the utility of fine-mapping in combination with
functional annotation for the refinement of GWAS signals
towards promising candidate causal variants, we present
detailed findings for four representative complex regions in
this manuscript. In the Chr2q31 region, we identified two
independent signals (Table 2 and Fig. 1C). The most strongly
associated SNP, rs13410475, is intronic in ITGA6 and in complete
LD with the original index SNP rs12621278 (r2 = 1). This signal
represents a tight cluster of four potentially causative variants.
The novel additional independent lead SNP, rs12151618, is
Table 1. Simple regions: fine-mapped regions where a single signal remained following stepwise logistic regression.
Chr (region) Previous hit Region boundary
(Hg19)
New index SNP (P-value) Alleles (ref/alt)—OR
(95% CI)
Imputation
quality r2-LD
r2 with
previous hit
Number of best
candidate SNPs
(number
overlapping bio-
features) [eQTLs]
1q21 (1_1) rs1218582 154334253–155332994 rs4845695 (2.7 × 10−8) A/G – 0.93 (0.90–0.95) 0.97–0.5 78 (26)
1q32 (1_2) rs4245739 203997926–204997638 rs199774366 (5.4 × 10−11) A/AAC—0.91 (0.88–0.94) 0.96–0.91 78 (22)
2p24 (2_2) rs13385191# 20388443–21388224 rs9306895 (6.5 × 10−10) T/C—0.92 (0.90–0.95) 0.92–0.58 5 (1)
2p21a (2_3) rs1465618 42985311–43984987 rs7591218 (3.8 × 10−10) A/G—1.09 (1.06–1.12) 0.99–0.34 8 (5)
2p11 (2_5) rs10187424 85294918–86293829 rs2028900 (3.1 × 10−16) T/C—0.90 (0.87–0.92) 0.90–0.83 42 (16)
2q37 (2_7) rs2292884 237943293–238943056 rs11891348 (2.1 × 10−8) T/G—0.92 (0.89–0.95) 0.94–0.40 36 (3) MLPH
3q13 (3_2) rs7611694 112775825–113775563 rs6769767 (1.3 × 10−15) A/G—0.90 (0.87–0.93) 0.94–0.83 14 (3)
4q13 (4_1) rs1894292 73692431–74691942 rs1894292 (1.4 × 10−11) A/G—0.92 (0.89–0.94) 1–n/a 11 (1)
4q24a (4_3) rs7679673 105561718–106561058 rs34480284 (8.0 × 10−29) T/TA—1.16 (1.13–1.18) 0.99–0. 98 13 (2)
5p15 (5_2) rs12653946# 1396112–2395482 rs10866527 (1.1 × 10−8) T/C—1.08 (1.06–1.11) 0.76–0.75 6 (3) IRX4
5p12 (5_3) rs2121875 43687710–44686471 rs1482679 (2.7 × 10−9) A/G—0.92 (0.89–0.95) 0.81–0.91 91 (0)
6p21 (6_1) rs130067& 30548676–31548176 rs2596546 (1.0 × 10−9) A/G—1.09 (1.06–1.12) 0.97–0.02 1 (0)
6p21 (6_2) rs3096702 31711572–32711433 rs115306967b (6.4 × 10−7) C/G—0.93 (0.90–0.96) 0.97–0.06 42 (9)
6p21 (6_3) rs1983891# 41036770–42036395 rs6458228 (4.7 × 10−8) A/C—1.08 (1.05–1.11) 0.92–0.90 33 (12)
6p21 (6_4) rs2273669 108785991–109784474 rs12209480b (8.9 × 10−7) A/G—1.12 (1.07–1.16) 0.88–0.39 4 (0)
6q22 (6_5) rs339331# 116827662–117827493 rs200820108 (2.0 × 10−10) A/ATT—0.90 (0.87–0.94) 0.91–0.64 34 (4)
6q21a (6_6) rs1933488 152941182–153941032 rs3968480b (8.9 × 10−7) A/G—0.90 (0.87–0.92) 0.97–0.92 54 (4) RGS17
7p15 (7_1) rs12155172 20529474–21529302 rs10713532 (4.1 × 10−14) T/TG—0.89 (0.86–0.92) 0.99–0.99 3 (1)
7q21a (7_3) rs6465657 97316451–98316171 rs6965016 (1.5 × 10−20) A/C—0.89 (0.86–0.91) 1–0.99 54 (15)
8p21 (8_2) rs11135910 25392758–26391862 rs6984769b (1.9 × 10−7) T/C—1.10 (1.06–1.13) 0.88–0.88 30 (5) EBF2
9q31 (9_1) rs817826& 109656878–110656064 rs1771718 (1.6 × 10−8) T/C—0.92 (0.89–0.95) 0.83–0.03 47 (31)
10q11a (10_1) rs10993994 51049548–52049482 rs10993994 (6.2 × 10−72) T/C—1.26 (1.24–1.29) 1–n/a 1 (1)
10q24 (10_2) rs3850699 103914882–104913940 rs34032774 (1.4 × 10−8) CT/C—1.09 (1.06–1.11) 0.91–0.94 33 (10) C10orf32/
TMEM180/AS3MT
10q26a (10_4) rs4962416 126447545–127446195 rs67609008b (6.0 × 10−5) T/C—0.94 (0.91–0.97) 0.97–0.42 10 (4) CTBP2
11p15a (11_1) rs7127900 1733857–2733077 rs11043143 (2.3 × 10−42) T/C—1.24 (1.21–1.27) 1–0.97 26 (16) ASCL2
11q22 (11_4) rs11568818 101902241–102901389 rs11568818 (2.0 × 10−10) T/C—1.09 (1.06–1.12) 1– n/a 2 (2) MMP7
12q13 (12_1) rs10875943 49176582–50175686 rs10875943 (4.2 × 10−12) T/C—0.91 (0.88–0.93) 1–n/a 6 (3)
12q13a (12_2) rs902774 52774067–53773299 rs73110471 (7.4 × 10−19) A/G—1.18 (1.14–1.22) 0.98–0.49 28 (6)
14q22 (14_1) rs8008270 52872457–53872104 rs62003539 (4.5 × 10−13) T/C—1.15 (1.11–1.19) 0.97–0.66 6 (1)
17p13 (17_1) rs684232 119162–1118931 rs461251 (6.2 × 10−15) A/G—0.90 (0.88–0.93) 1–0.90 13 (5)
VS53/FAM57A
17q24a (17_4) rs1859962 68609232–69608508 rs8072735 (2.4 × 10−50) T/C—1.21 (1.19–1.24) 0.99–0.76 19 (9)
18q23 (18_1) rs7241993 76177342–77176537 rs9959454 (3.9 × 10−9) A/G—1.09 (1.06–1.12) 1–0.81 12 (3)
19q13a (19_1) rs8102476 38235839–39235539 rs12610267 (3.7 × 10−13) A/G—1.10 (1.07–1.12) 0.95–0.81 15 (6) CATSPERG
19q13a (19_2) rs11672691 41485821–42485578 rs74738513 (2.5 × 10−12) A/T—0.90 (0.87–0.93) 0.85–0.98 8 (4)
20q13 (20_2) rs6062509 61863226–62862439 rs1058319 (1.4 × 10−14) T/C—0.84 (0.80–0.88) 0.85–0.22 1 (1)
22q13 (22_1) rs9623117 39952275–40952051 rs11704314b (1.7 × 10−6) A/G—0.92 (0.88–0.95) 0.86–0.06 2 (2)
Xp22 (23_1) rs2405942 9314154–10314083 rs2405943 (3.1 × 10−11) T/C—0.93 (0.91–0.95) 1–0.90 10 (0)
Xp11a (23_2) rs5945619 50742323–51741595 rs1541241 (8.0 × 10−33) T/G—1.12 (1.10–1.14) 1–0.95 93 (0)
Xq12 (23_3) rs5919432 66522881–67520014 rs4446868 (3.6 × 10−8) T/G—0.93 (0.90–0.96) 0.77–0.55 46 (0)
Fine-mapping identified a single, more strongly associated variant at 39 regions. Imputation quality and correlation (LD) between these and the original GWAS signal are
indicated. We confirmed association with PrCa in populations of European ancestry for one variant originally identified in #Japanese and one variant reported for
&Chinese individuals, which had not been reported for Europeans previously. Four variants previously reported for Japanese or Chinese ancestry populations showed
no evidence for replication in Europeans in this analysis (see Supplementary Material, Table S1). The KLK region at Chr19 was not included here as this region had
previously been fine-mapped individually (5). Best candidate SNPs are variants correlated at r2 > 0.7 with the lead variant describing an association, and with odds of
association ≥1/1000 relative to the lead variant for the region.
eQTL data indicate statistically significant correlation between the new index SNP and gene expression in 145 prostate tumor samples from the TCGA dataset.
aThese regions were densely genotyped on the iCOGS chip to fine-map PrCa associations known at the time of design.
bThe top SNP in these six regions did not achieve genome-wide significance in iCOGS/UKGWAS but was significant in a larger meta-analysis study (4).
Human Molecular Genetics, 2015, Vol. 24, No. 19 | 5593
Table 2. Complex regions: multiple independent associations were identified in 16 regions following stepwise logistic regression.
Chr (region) Previous hit(s) Region boundaries
(Hg19)
Best signal in meta-
analysis (P-value)
Independent lead SNPs Alleles (ref/alt)—OR
(95%) in the final model
Imputation quality r2:
LD (r2) with original index
SNP (first/second original
SNP): LD (r2) with new
best signal
Number of best
candidate SNPs
(number overlapping
bio-features) [eQTLs]
2p15a (2_4) rs721048 62631731–63631731 rs58235267 (3.9 × 10−26) rs58235267 (3.1 × 10−21) C/G—0.88 (0.85–0.90) 0.88: 0.12: n/a 1 (1)
rs901532 (3.5 × 10−6) T/C—1.10 (1.06–1.14) 0.99: 0.07: 0.03 3 (1) EHBP1
2q31a (2_6) rs12621278 172811553–173811553 rs13410475 (8.3 × 10−26) rs13410475 (2.1 × 10−15) A/C—0.78 (0.72–0.84) 0.97: 1: n/a 74 (18)
rs12151618 (3.36 × 10−7) T/C—0.92 (0.88–0.95) 0.93: 0.09: 0.09 4 (0)
2q37 (2_8) rs3771570 241882864–242882864 rs111770284 (1.6 × 10−13) rs111770284 (3.03 × 10−12) T/C—1.13 (1.10–1.17) 0.85: 0.03: n/a 4 (3)
rs183997311 (8.63 × 10−8) A/G—0.67 (0.53–0.82) 0.58: 0.002: 0.002 7 (2)
3p12a (3_1) rs2660753
rs2055109
86610674–87967332 rs2088396 (6.5 × 10−23) rs2088396 (5.75 × 10−15) C/G—0.90 (0.88–0.93) 0.99: (0.03/0.01): n/a 17 (0)
rs143351723 (2.88 × 10−10) C/G—0.85 (0.80–0.90) 0.97: (0.36: 0.03): 0.06 51 (5)
rs114278123 (1.75 × 10−5) A/G—0.86 (0.79–0.93) 0.99: (0/0): 0.008 7 (2)
3q21a (3_3) rs10934853 127710474–128284711 rs2811485 (1.1 × 10−15) rs2811485 (4.76 × 10−15) T/G—1.12 (109–1.15) 0.99: 0.81: n/a 78 (10)
rs56325233 (2.21 × 10−6) C/G—1.07 (1.04–1.10) 0.94: 0.003: 0.0007 28 (0)
3q26a (3_5) rs10936632 169689793–170395852 rs78416326 (6.4 × 10−25) rs78416326 (1.8 × 10−28) C/G—0.83 (0.79–0.86) 0.80: 0.13: n/a 2 (0)
rs11288195 (7.49 × 10−9) A/AG—1.12 (1.08–1.16) 0.98: 0.122: 0.028 2 (1)
4q22a (4_2) rs12500426
rs17021918
95018784–95600782 rs7682375 (4.0 × 10−19) rs7682375 (1.10 × 10−6) A/T—1.09 (1.05–1.12) 1: (0.38/0.69): n/a 20 (6) BMPR1B
rs6853490 (4.78 × 10−6) A/G—0.93 (0.90–0.96) 0.95: (0.76/0.24): 0.30 7 (3) BMPR1B
6p25a (6_7) rs9364554 160374745–161323288 rs4646284 (3.2 × 10−47) rs4646284 (5.40 × 10−38) T/TG—0.81 (0.78–0.84) 0.77: 0.04: n/a 1 (1)
rs2063347 (4.58 × 10−7) A/G—1.07 (1.04–1.10) 1: 0.58: 0.022 18 (8)
7p15a (7_2) rs10486567 27550633–28102614 rs10486567 (7.3 × 10−22) rs10486567 (2.62 × 10−15) A/G—0.88 (0.85–0.91) 1: 1: n/a 22 (7)
rs200362064 (9.04 × 10−6) T/TGATA—0.94 (0.92–0.97) 0.97: 0.034: 0.034 15 (6)
8p21a (8_1) rs2928679
rs1512268
23100674–23548146 rs13272392 (1.3 × 10−26) rs13272392 (8.7 × 10−31) A/T—0.86 (0.83–0.89) 1: (0.00003/0.99): n/a 15 (3) LOXL2
rs200262583 (3.22 × 10−12) A/AGTCCTCCTTTTCTT—
0.90 (0.87–0.93)
0.88: (0.374/0.018): 0.019 49 (31)
11q13a (11_3) rs7931342
rs10896438
rs12793759
68811777–69494148 rs12275055 (4.7 × 10−53) rs12275055 (6.1 × 10−23) A/G—0.83 (0.79–0.87) 1: 0.19: n/a 5 (1)
rs10792032 (3.5 × 10−17) A/G—1.13 (1.10–1.16) 0.97: 0.90: 0.19 30 (4)
rs36225067 (1.34 × 10−8) A/C—0.80 (0.73–0.88) 0.75: 0.002: 0.002 16 (13)
12q24 (12_3) rs1270884 114632506–115103229 rs1270884 (6.8 × 10−9) rs1270884 (1.34 × 10−8) A/G—1.08 (1.05–1.10) 1: 1: n/a 23 (0)
rs61933115 (7.58 × 10−6) A/G—1.09 (1.05–1.13) 0.52: 0.0008: 0.0008 1 (0)
14q24 (14_2) rs7141529 68974508–69135467 rs7141529 (6.5 × 10−11) rs7141529 (5.27 × 10−12) T/C—0.92 (0.89–0.94) 1: 1: n/a 2 (1)
rs2189517 (7.80 × 10−6) A/G—1.06 (1.03–1.09) 0.96: 0.002: 0.002 8 (1)
rs17105852 (7.16 × 10−5) A/C—0.86 (0.79–0.94) 0.97: 0.001: 0.001 1 (1)
17q12a (17_2) rs11649743
rs4430796
35740855–36249855 rs11263763 (2.1 × 10−66) rs11263763 (1.0 × 10−62) A/G—1.25 (1.22–1.27) 0.97: (0.008/0.94): n/a 5 (3)
rs718961 (5.35 × 10−12) A/G—0.90 (0.87–0.93) 0.98: (0.76/0.005): 0.005 4 (4)
rs2229295 (3.75 × 10−7) T/G—1.10 (1.06–0.13) 0.96: (0/0): 0.0003 1 (1)
17q21 (17_3) rs11650494 46845186–47936749 rs138263737 (7.0 × 10−12) rs138263737 (5.7 × 10−10) T/C—1.93 (1.72–2.14) 0.60: 0.002: n/a 1 (0)
rs11655191 (1.82 × 10−7) T/C—1.13 (1.09–1.18) 0.96: 0.76: 0.0004 70 (20) ZNF652
22q13 (22_2) rs5759167 43000212–44000212 rs5759167 (1.8 × 10−29) rs5759167 (6.5 × 10−24) T/G—0.87 (0.85–0.90) 1: 1: n/a 2 (1)
rs5751435 (4.55 × 10−10) T/C—0.88 (0.84–0.92) 0.98: 0.02: 0.02 15 (6) TTLL12/MCAT
Following multiple stepwise logistic regression analyses, multiple independent association signals were identified in 16 regions. The TERT at Chr5p15 and Chr8q24 regions which are also known to harbor multiple independent PrCa
susceptibility loci were not included in this analysis as they had previously been fine-mapped individually (6,7). Imputation quality and correlation (LD) between the novel lead SNPs and the original GWAS signal(s) are indicated, as are
the correlations between the most strongly associated variant in this analysis and the additional independent hits within the region.
Best Candidate SNPs are variants correlated at r2 > 0.7 with the lead variant describing an association, and with odds of association ≥1/1000 relative to the lead variant for the region. eQTL data indicate statistically significant
correlation between the new index SNP and gene expression in 145 prostate tumor samples from the TCGA dataset.
aThese regions were densely genotyped on the iCOGS chip to fine-map PrCa associations known at the time of design.
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weakly correlated with this signal (r2 < 0.07) and situated 5 kb
upstream of PDK1 (pyruvate dehydrogenase kinase isozyme 1)
in the promoter region. PDK1 is believed to be upregulated by
Myc and HIF-1 to facilitate cell survival and proliferation under
hypoxia, and is reported to be commonly overexpressed in
cancer cells (21,22).
Two independent signals were also identified at Chr2q37,
where the previously reported hit rs3771570 was intronic in
FARP2 (Table 2 and Fig. 1D). In our analysis, the most strongly as-
sociated novel lead SNP, rs111770284, is not in LDwith the origin-
al GWAS hit (r2 = 0.03). rs111770284 is intronic in ANO7 (also
known as NGEP, New Gene Expressed in Prostate), overlaps a
Figure 1. Locus explorer plots of two simple and four complex regions. (A) Region 23_3 at ChrXq12, (B) Region 9_1 at Chr9q31, (C) Region 2_6 at Chr2q31, (D) Region 2_8 at
Chr2q37, (E) Region 14_2 at Chr14q24 and (F) Region 17_2 at Chr17q12. For regions containing multiple independent association signals, the separate lead SNPs are
indicated and colored red, blue, green, orange and purple, respectively. Original GWAS tag SNPs that were replaced during fine-mapping are marked in gray on the plot.
Clusters of correlated variants for each signal are distinguished using different colors in the plot and on the panel below, including for the original GWAS SNPs. Stronger
shading indicates greater correlation with the lead SNP, with variants not correlated at r2≥ 0.5 with any lead SNP uncolored. Directly genotyped variants are denoted as
triangles and imputed variants as circles. Log10 P-values are shown on the Y-axis of the plot. Colored arrows within the plot mark SNPs that overlap with regulatory
elements in ENCODE; red for 3′UTRs, blue for coding variants, purple for promoters and orange for miRNA sites. The position of genes within the region and the genomic
coordinates of the plot are shown on the lower panel, with genes on the positive strand in green and the negative strand in purple. The LNCaP track shows the density of
annotated bio-features within the LNCaP cell-line (data from ENCODE).
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DNase1 site in LNCaP and implicates a set of four correlated var-
iants as putative functional candidates. ANO7 is an androgen
regulated gene and its expression appears to be prostate specific
(23,24), with reduced expression associated with increased PrCa
malignancy (25). The second independent signal, rs183997311,
is intronic in FARP2. This variant is not in LD with either the ori-
ginal GWAS tag SNP or rs111770284. rs183997311 is relatively rare
(MAF = 1%) and is correlated to two variants that overlap regula-
tory elements in LNCaP. It is also notable that the original hit
rs3771570 was excluded from our list of best candidate causal
SNPs after fine-mapping of this region.
At Chr14q24, the original signal rs7141529 remained themost
significantly associated variant after stepwise logistic regression;
however, two further additional independent signals described
by rs2189517 and rs17105852 were identified (Table 2 and
Fig. 1E). These novel variants are both situated within the same
long intron of RAD51B but are not correlated with each other or
with rs7141529. This region also harbors two independent risk
signals for breast cancer, one of which is additionally associated
with breast cancer in males; however, there is no correlation
between these variants and any of the three PrCa risk SNPs
(26,27) (Supplementary Material, Fig. S3).
The HNF1B locus on Chr17q12 contained two previously re-
ported independent signals for PrCa.We identifiedmore strongly
associated lead SNPs to describe these signals, while the original
GWAS SNPs were also excluded from the list of best candidate
variants. The novel lead SNPs, rs11263763 in the first intron and
rs718961 in the fourth intron, each overlap withmultiple bio-fea-
tures and therefore themselves represent good causal candi-
dates, although both are also correlated to a modest number of
other promising candidates (Table 2; Supplementary Material,
Table S2). In addition to these refinements of the original signals,
we have identified a previously unknown third independent as-
sociation described by rs2229295, which lies within the 3′UTR
ofHNF1B andmay itself represent a strong candidate causal vari-
ant worthy of further investigation (Fig. 1F).
To further interrogate the variants in our best candidate list
for potential functional effects, we examined TCGA data from
145 prostate tumor and 45 normal prostate tissue samples for dif-
ferential expression of nearby genes associated with these SNPs.
Figure 2. Circos plot overview of functional annotation and eQTL data for fine-mapped PrCa risk loci generated usingCircos (http://circos.ca/, 62). The outer ring is a circular
ideogram of the human genome annotated with chromosome number. The positions of the novel index SNPs for PrCa susceptibility identified through fine-mapping are
indicated adjacent to this and are color coded for overlap with enhancer elements in LNCaP in orange, promoter regions in green, coding SNPs in red, variants within UTR
regions in purple and variants with no annotated functionality in black. The inner ring denotes potential candidate genes for the refined PrCa regions. Genes for which an
SNP in the best candidate list is a significant eQTL in prostate tissue in TCGAdata are indicated in red, eQTLs in skin tissue fromEuroBATS data aremarked in brown, eQTLs
for both prostate and skin in green and for regions with no significant eQTL in either tissue the closest flanking gene is indicated in black. Gene interaction networks
between potential candidate genes are shown as links in the central portion of the plot. The genes annotated on the inner ring were used to construct a network using
the BioGRID interaction database filtered to exclude ubiquitin and interactions with more than a single intervening gene between the candidate genes. Red links
indicate an interaction network with the AR gene, other examples of interaction highlighted in color: blue—RAD23B, green—BMPR1B, orange—PDK1 and all other
interactions are marked in gray.
5596 | Human Molecular Genetics, 2015, Vol. 24, No. 19
We observed significant associations with gene expression for 16
of our association signals (Fig. 2, Tables 1 and 2; Supplementary
Material, Table S2). Several of these eQTLs have been reported
previously (28,29) and most recently Li et al. described significant
eQTLs at 31 of 69 PrCa GWAS regions they tested (45%), imple-
menting a mapping strategy for 19 of these regions which se-
lected candidate causal variants ranging from 1 to 33 SNPs
(30,31). Here, we report prostate tissue eQTLs at ∼20% of the loci
we analyzed; however, this is likely to be an underestimate due to
the relatively small set of prostate samples currently available in
TCGA (30). We subsequently examined EuroBATS (32,33) eQTL
data for a much larger set of samples from lymphoblastoid cell
lines (814 samples), skin (716 samples) and adipose (766 samples)
tissues in order to investigatewhether anyof the eQTLs identified
in the TCGA prostate tumor tissue dataset act ubiquitously and
also whether additional signals are present within these tissues
that might also be detectable in a larger set of prostate samples.
Only one region (Chr10q24 for C10orf32) showed evidence for ubi-
quitous eQTL association in all four tissue types interrogated.
There were nine signals across seven regions which had at least
one concordant eQTL between the TCGA PRAD tumor and any
tissue type in EuroBATS. Of the eQTL signalswhich are confirmed
in both TCGA and at least one EuroBATS tissue, five have been de-
scribed before using the TCGA dataset (AS3MT,VPS53,MLPH, IRX4
and RGS17) (30). We therefore consider the four novel signals
identified here (C10orf32, TMEM180, MMP7 and TTLL12) as robust
candidates for functional follow-up, especially due to the large
sample set used in the EuroBATS project (Supplementary Mater-
ial, Table S2). TTLL12 is a particularly interesting candidate sus-
ceptibility gene as its expression has been shown to increase
during cancer progression and metastasis (34). In addition to
these eQTLs replicated between the two separate datasets, we
also report a strong eQTL for ZNF652 within the TCGA prostate
tissue data solely. We have also detected eQTLs for RAD51Bwith-
in the EuroBATS data only and for RAD23B in normal prostate
TCGA data, but not in prostate tumor. These potentially interest-
ing associations may therefore warrant further follow-up within
a larger prostate tissue set. In the central portion of our circos plot
(Fig. 2), wehave illustrated potentially interesting interaction net-
works between the candidate genes identified through this fine-
mapping study. This highlights in particular that a large number
of these plausible candidate genes are regulated by the AR, as
shown in red.
To evaluate whether the refinement of previously identified
PrCa loci that we have achieved in this study reflects a greater
enrichment towards variants with annotated functionality, we
assessed our list of 1623 best candidate SNPs for overlap with
bio-features and compared this against the full set of imputed
SNPs within the 55 regions that were significant in this analysis
(243 627 SNPs). Using the hypergeometric test, we observed a sig-
nificant enrichment inoverlapwithbio-features for the variants in
our best candidate SNP list (P = 2.01 × 10−20, SupplementaryMater-
ial, Fig. S4). This enrichment was even stronger when only enhan-
cer elements were included in the analysis (P = 1.67 × 10−27).
In order to estimate the extent towhich fine-mapping of these
known PrCa susceptibility regions could improve understanding
of the genetic factors that influence PrCa risk, we compared the
FRR of PrCa explained by the original GWAS tag SNPs with the
FRR explained by the novel lead SNPs that we have identified in
this study. We used estimated variant effect sizes and allele fre-
quencies from the samples in the iCOGS study to calculate both
estimates to avoid the potential for inflation from the UK GWAS
study. We accounted for the LD between variants in the complex
regions containing more than one independent SNP to avoid
overestimating FRR. The estimated FRR explained when substi-
tuting for our refined lead SNPs and introducing the newly iden-
tified independently associated variants from this study was
38.9%, compared with 30% for the originally reported GWAS tag
SNPs; an improvement of 8.9% overall, and nearly a third greater
than had been previously attributed to these known PrCa suscep-
tibility signals.
Discussion
In this study, we used imputation of existing genotype data to
fine-map 64 PrCa GWAS regions in European ancestry popula-
tions comprising 25 723 PrCa cases and 26 274 controls from
three studies (iCOGS and UK GWAS Stages 1 and 2). Twenty-
three of these regions were fine-mapped at very high resolution
on the iCOGS chip. Nine previously reported GWAS signals were
not replicated at genome-wide significance in this study due to
either decreased power in comparison with the original studies
or having only previously been associated with PrCa susceptibil-
ity in a non-European population.
In 39 of the remaining 55 regions, we found evidence for a
single PrCa association signal only. The original GWAS tag SNP
remained the most significant association for just 4 of these,
while at 35 regions, we identified a more significantly associated
replacement lead SNP. Importantly, we also identified 16 complex
regions containing multiple variants independently associated
with PrCa. Only five of these had previously been identified as
containing multiple independent variants (Chr3p12, Chr4q22,
Chr8p21, Chr11q13 and Chr17q12); however, our analysis helped
to further refine these five regions and identified one additional
previously unknown hit at Chr17q12 within the promoter region
of HNF1B. For the remaining 11 complex regions, this study pro-
vides the first evidence for the presence of multiple independent
PrCa susceptibility variants in close genomic proximity to one an-
other. An alternative explanation for the observation of multiple
apparently independent association signals would be that both
could in fact bemoderately correlatedwitha single untypedcausal
variant, despite exhibiting limited LD between themselves (35,36).
We believe that this hypothesis is unlikely to underpin a substan-
tial proportion of the multiple signals we have observed in this
study, since 11 of the 16 identified complex regions had been
densely genotypedon the iCOGSarray, enablingvery thorough im-
putation of additional untyped variants within the region. How-
ever, this phenomenon cannot be completely excluded without
deep re-sequencing of each of these loci in a large sample panel,
which would facilitate the evaluation of all correlated variation
within the region and subsequently the identification of the pre-
cise causal variants. Our functional annotation of the statistically
most promising correlated candidate causal variants also provides
provisional evidence to implicate a contribution by several new
potential candidate genes in PrCa risk.
We have annotated our set of statistically significant SNPs in
order to prioritize themost likely candidate causal variants with-
in each region. We firstly excluded all SNPs that were associated
with PrCa risk at a conservative threshold of ≤1/1000 compared
with the association likelihood of the novel lead SNP for each
signal. This generated a list of 6537 variants across the 55 sig-
nificantly associated regions in our final analysis. To further
prioritize within this list, we trimmed based on LD structure
and selected only those variants that were strongly correlated
(LD r2 > 0.7) with the lead SNP based on 1 KG EU data. The inter-
section of these two selection criteria generates a list of 1623 var-
iants, which we would expect to retain and be enriched for the
causal functional variants. However, we cannot exclude the
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possibility that in some instances the causal variant(s) may be in
lower LDwith the novel index variants, particularly in the regions
that were less densely genotyped. In addition, our imputed asso-
ciation datamay be underpowered to detect any instances where
rare causal variants give rise to the association signal through a
‘synthetic association’ (37). The incorporation of functional anno-
tation in addition to statistical data and LD criteria may also help
to further prioritize our list of the best candidate SNPs for PrCa risk
causality towards those with the strongest evidence for biological
effect, to facilitate potential laboratory follow-up. For 62 of the 75
independent association signals we detected, one or more of the
best candidate variants in our list overlaps with bio-features in
PrCa cell lines (413 of the 1623 variants were annotated for func-
tionality in total,medianof 4per signal).We furthermoreobserved
eQTLs for differential gene expression in TCGA prostate tumor or
normal tissue forone ormore variants in our best candidate list for
16 of these 75 independent association signals, with additional
eQTLs at other regions also observed within a larger set of Euro-
BATS data for three additional tissues.
An important aspect of this mapping study is the improve-
ment of the estimated FRR of PrCa explained by the refined and
newly identified independently associated variants. This is now
substantially higher, at ∼39% compared with 30% estimated for
the original GWAS tag SNPs (12). Fine-mapping of these 55
known regions has therefore improved our understanding of
the genetic basis of PrCa and incorporating these novel variants
into future risk models should enhance the capability to predict
individuals at greater risk. It is also interesting to note that of the
23 regions analyzed in this study that were known at the time of
design of the iCOGS array and therefore fine-mapped through a
more dense set of directly genotyped markers; these represent
11 of the 16 complex regions and only 12 of the 39 simple regions.
This might suggest that the presence of multiple independent
PrCa susceptibility variants within previously identified GWAS re-
gions could be even more widespread than we have been able to
identify in this fine-mapping study. Consequently, additional sus-
ceptibility signals could yet reside within the regions that remain
to be interrogated through very dense marker resolution in a suf-
ficient sample size; an experimentwhich is currently being under-
taken by the OncoArray Consortium (38).
A concurrent PrCa fine-mapping study by Han et al. (Hum. Mol.
Genet., submitted) has examined 69 risk regions among a multi-
ethnic sample panel comprising European (8600 cases and 6946
controls), African (5327 cases and 5136 controls), Asian (2563
cases and 4391 controls) and Latino (1034 cases and 1046 con-
trols) ethnicities. After performing a meta-analysis for marginal
tests across multiple populations 12 regions were not significant,
while a single novel, more significantly associated lead SNP was
identified at 32 of the 57 significant regions (56.1%). In compari-
son, across the 55 regions that achieved genome-wide signifi-
cance in our study, the original GWAS tag SNP was replaced
with a more significantly associated SNP at 47 (85.4%). For the
46 significant regions that overlapped between these two studies’
final datasets, 32 of the refined SNPs identified by Han et al. were
among our list of best candidate SNPs (69.5%). Within these over-
lapping regions, we identified 12 novel independent signals, 9 of
which were nominally significant in the multi-ethnic fine-map-
ping but nonewere included in their top order or putatively func-
tional SNPs. Comparing final putative functional candidates for
the 46 overlapping regions, 29 (63.0%) of these regions have at
least one overlapping functional candidate SNP. More notably,
11 of these 46 regions (23.9%) have a single overlapping functional
candidate SNP, which should therefore be assigned high priority
as potential causal candidates for future experimental follow-up.
Overall, the comparisons between these two approaches high-
light the increased power provided by the larger sample set avail-
ablewithin our study; in particular in respect to the identification
of multiple independent association signals within already
known regions, but also demonstrate that the ability to incorpor-
ate multiple ethnic populations may further improve the effi-
ciency of fine-mapping. This suggests that large meta-analysis
based fine-mapping studies comprising individuals of diverse
ancestries may represent the most robust strategy for imput-
ation-based fine-mapping where such data are available.
In conclusion, we have demonstrated the importance of geno-
typing and imputation-based fine-mapping through the discovery
of 12 additional independent PrCa associations within known
GWASregions andby refining thevastmajorityof thepreviously re-
ported signals. Before fine-mapping efforts were employed, poten-
tial causal SNPs at each susceptibility locuswere selected primarily
on the basis of high correlation to the reportedGWAS tag SNP (14) or
overlap with functional elements; this strategy can however either
introduce substantial noise or a greater likelihood of excluding true
causal variants, due to the lack of statistical evidence available
when retaining or excluding non-genotyped variants. Through
coupling functional annotation and LD information to our imputed
association dataset, we believe we have been able to enrich for the
most likely candidate causal PrCa susceptibility variants at each as-
sociation signal while substantially reducing noise within the list.
Indeed, this approach selected only a modest number of SNPs per
locus, yet these showed evidence for modulating differential gene
expression and greater overlap with bio-features in prostate data-
sets. While complete re-sequencing of GWAS regions in large sam-
ple sets would ultimately be desirable, our approach undoubtedly
represents the most time and cost-effective method available at
the present time to interrogate and prioritize the most plausible
causal variants underpinning GWAS studies. We have demon-
strated that many of the GWAS regions identified to date for PrCa
harbored additional, previously hidden independent association
signals, with perhaps more yet to be discovered. This observation
may have important implications towards the deconvolution of
the functional mechanisms underlying these signals, and in par-
ticular could help to facilitate improved risk prediction, since
these additional independent association signals could account
for a significant proportion of the missing heritability of PrCa and
other complex diseases (39).
Materials and Methods
Samples
Analyses were based on data from the iCOGS array, a custom
array comprising ∼200 000 SNPs designed to study susceptibility
to prostate (PRACTICAL Consortium), breast and ovarian cancers
(12), together with data from a UK GWAS study (Stage 1) and sub-
sequent custom array designed as a replication stage of the Stage
1 GWAS that was genotyped in studies from the UK and Australia
(Stage 2). The analyses presented here were restricted to 51 997
men (25 723 cases and 26 274 controls) of European ancestry, sam-
pleswith other ethnicity in the iCOGS studywere small in number
and were included in a separate study addressing mapping using
multi-ethnic sample sets (Han et al., Hum. Mol. Genet., submitted).
See Eeles et al. (12) for details of thequality control (QC)procedures.
After QC, data were available for 11 338 samples (5504 cases and
5834 controls) from the GWAS, and 40 659 samples (20 219 cases
and 20 440 controls) from 32 studies in PRACTICAL genotyped
using the iCOGS array. The majority of studies were population-
or hospital-based case–control studies, or nested case–control
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studies, but some studies selected samples by age or oversampled
for cases with a family history; in the latter instance only one case
per family was genotyped (Supplementary Material, Table S5).
Only the 40 659 iCOGS samples were used for the FRR estimation
to avoid inflation from the Stage 1 GWAS.
Genotyping
UK GWAS Stages 1 and 2 were genotyped using the Illumina Infi-
nium HumanHap550 and a custom Illumina iSELECT array,
respectively (17,40).
iCOGS genotyping was conducted using a custom Illumina In-
finium array (iCOGS) in seven centers, of which five were utilized
for PRACTICAL. Genotypes were called using Illumina’s propri-
etary GenCall algorithm. In addition to SNPs selected for replica-
tion of GWAS, the iCOGS array included dense sets of SNPs
surrounding susceptibility variants known at the time of design.
For PrCa, we included 23 such regions (ccge.medschl.cam.ac.uk/
research/consortia/icogs/). To select markers for comprehensive
interrogation of these densely genotyped regions, we identified
all known SNPs from theMarch 2010 release of the 1000 Genomes
Project with MAF > 0.02 in Europeans and selected all SNPs that
were correlated with the published GWAS SNPs (at r2 > 0.1); to-
gether with a set of SNPs designed to tag all remaining variants
at r2 > 0.9. Approximately 14 000 SNPswere successfully designed
across these regions.
Statistical methods
The primary genotype data were used to impute genotypes for
∼17 M SNPs/indels using the 1000 Genomes Project (March 2012
release) as a reference panel and IMPUTE V2 (41). Imputation
was carried out using pre-phasing with 50 iterations and all
known PrCa regions were imputed in an ∼5Mb block size. Per-
allele odds ratios and standard errors were estimated for each
SNP by logistic regression. Analysis was stratified by study and,
for both the GWAS and iCOGS, included eight principal compo-
nents as covariates. We included imputed data for SNPs with
quality information scores >0.3. Analyses were performed using
SNPTEST (42). Results from the iCOGS and GWASwere then com-
bined in a fixed effect meta-analysis using METAL (43).
Comparison of number of associated loci among cancer-
specific regions
To establish a suitable significance threshold, we examined 59
known breast cancer regions with no known association with
PrCa prior to this analysis. Regions were defined as a ±500 kb
boundary around the published breast cancer GWAS SNPs. We
interrogated our meta-analysis results (iCOGS and Stages 1 and
2 UK GWAS) in order to establish the likelihood that SNPs within
these breast cancer regions would be associated with PrCa by
chance at P ≤ 10−5 level. Performing this comparison revealed
that an association P = 10−5 was sufficiently strict for the avoid-
ance of false-positive results in the discovery of secondary sig-
nals within a region after adjusting for the top signal variant.
Identification of lead SNPs within each region
To identify independent association signals within a region, we
selected all significant SNPs with P≤ 10−5 from the fine-mapping
dataset (iCOGS, Stages 1 and 2 GWAS) and performed a stepwise
logistic regression on this set of SNPs for each region. For regions
inwhich the initial analysis indicatedmore than one independent
SNP, a second round stepwise logistic regressionwas performed to
confirm the presence of additional independent SNPs, after ad-
justing for the best signal in the region. SNPs with P ≤ 10−5 from
the adjusted results were included in this analysis, alongside the
top hit. For regions found to containmultiple independently asso-
ciated SNPs, haplotype-specific odds ratios were estimated based
on the independent SNPs identified through the stepwise logistic
regression analysis, using the Haplo.Stats package (http://cran.r-
project.org/web/packages/haplo.stats/index.html) (44). SNPs with
a likelihood ratio of≥1/1000 relative to themost significant SNPde-
scribing each signal were selected as potential candidate causal
variants (45). This list was narrowed down further by filtering var-
iants at LD r2 < 0.7 with the lead SNPs to curate a list of best candi-
date causal SNPs for each signal. For regions with multiple
independent SNPs, the lists for the subsequent signals were gen-
erated bydetermining the likelihood ratio relative to the top SNP in
that region, adjusted forother signals.We excludedduplicates and
used a cut-off P = 6.7 × 10−5 (P-value for odds of >1/1000 relative to
the genome-wide significance level of 5 × 10−8) to trim the list
where there was a second signal that did not reach the genome-
wide significance level (5 × 10−8).
Contribution to familial risk
The contribution of SNPs to the familial risk of PrCa, under a
multiplicative model, was computed using the formula
P
k log λk
log λ0
;
where λ0 is the observed familial risk to first-degree relatives of
PrCa cases, assumed to be 2 (46,47), and λk is the FRR due to
locus k. For a single SNP, λk is given by
λk ¼
pkr2k þ qk
ð pkrk þ qkÞ2
where pk is the frequency of the risk allele for locus k, qk ¼ 1 pk
and rk is the estimated per-allele odds ratio, estimated from the
logistic regression model for that SNP. For regions with more
than one SNP in LD, we used the extended formula:
λk ¼
P
j pkjr
2
kj
ðP j pkjrkjÞ2
where pkj is the frequency of haplotype j for the multi-locus re-
gion k and rkj is the corresponding risk estimate. The haplotype
frequencies were estimated using Haplo.Stats, while the haplo-
type-specific risk estimates were based on the regression ana-
lyses, thus preserving the assumption of a log-additive effect of
all SNPs.
Locus explorer
We developed Locus Explorer, a Shiny web application for R, to
generate the locus plots shown in this manuscript. Locus Explor-
er can be run locally using R studio with the necessary packages
installed. The code is available on GitHub. The application is
interactive and enables selecting and zooming on the locus, se-
lecting annotation tracks and downloading the resulting plots
and the data used for plotting. Data for plotting are stored in
SQLite database which is accessed using R scripts. Plots are dis-
played mainly using RStudio, sqldf, ggplot and ggbio (48–51). At
the time of submission, the application is currently in Beta
stage for external users, withmost functionality in place and per-
formance issues resolved. We are continuously working on
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additional features and for future versions themain focus will be
speed of the plotting process. More information is available at
GitHub (https://github.com/oncogenetics/LocusExplorer).
Functional annotation
We used a number of publicly available prostate epithelia and
PrCa ENCODE datasets of chromatin features to identify putative
regulatory regions at each risk locus (14,52). The integration of
chromatin bio-feature annotations with SNP positions was per-
formed using FunciSNP (53). These datasets included LNCaP
and RWPEI DNase I HS sites (GSE32970) ENCODE; PrEC DNase I
HS sites (GSE29692) ENCODE; LNCaP CTCF ChIP-seq peaks
(GSE33213) ENCODE; LNCaP H3K27ac and TCF7L2 (GSE51621)
(14), H3K4me3 and H3K4me1 histone modification ChIP-seq
peaks (GSE27823) (54); FoxA1 ChIP-seq peaks (GSE28264) (55); AR
ChIP-seq peaks (56) and AR binding sites (GSE28219) (57); NKX3-1
ChIP-seq peaks (GSE28264) (55). We also used the highly con-
served set of predicted targets of microRNA targeting (miRcode
11 June 2012 release) (58). To determinewhether any of the puta-
tive functional SNPs potentially affect the binding of known tran-
scription factors, position-specific frequency matrices were
employed from Factorbook (14,59).
cis-eQTL analysis
A/TCGA PRAD samples
The genotypes of the variants in the best candidate SNP list in 145
prostate tumor samples and 45 normal tissue samples were
downloaded from TCGA database (Feb 2013). All samples were
verified as Caucasian descendants. If a variant was not repre-
sented in the TCGA data, the genotypes were imputed using IM-
PUTE2. A cis-eQTL analysis was performed for these variants and
any transcript within a 1 Mb interval (500 kb on either side). The
abundance of the transcripts is adjusted for somatic copy num-
ber changes and CpG methylation changes using methods de-
scribed previously. The nominal P-values obtained for each risk
variant were corrected for the number of transcripts in the inter-
val using Benjamini–Hochberg method. Significant associations
were defined as a false discovery rate < 0.05.
B/EuroBATS samples
The sample set includes LCLs (N = 814), skin (N = 716) and adipose
tissue (N = 766) derived simultaneously from a subset of well-
phenotyped healthy female twins (32,33). eQTL discovery is de-
scribed in detail elsewhere (32). In short, (i) we kept the residuals
of amixedmodel that removed the effects of the family structure
using the implementation in GenAbel R package. (ii) We per-
formed a linear regression of those residuals on the SNPs in a
1 Mb window around the transcription start site for each gene,
using MatrixeQTL R package (60). We assessed statistical signifi-
cance through 2000 permutations. Prior to the analysis, we re-
moved the effects of technical covariates using the factor
analysis strategy implemented in PEER (61) and transformed
the data using a rank normal transformation.
Supplementary Material
Supplementary Material is available at HMG online.
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